File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Intracellular levels of hepatitis B virus DNA and pregenomic RNA in peripheral blood mononuclear cells of chronically infected patients

TitleIntracellular levels of hepatitis B virus DNA and pregenomic RNA in peripheral blood mononuclear cells of chronically infected patients
Authors
KeywordsChronic hepatitis B
Hepatitis B virus DNA
Peripheral blood mononuclear cells
Pregenomic RNA
Issue Date2009
PublisherBlackwell Publishing Ltd
Citation
Journal Of Viral Hepatitis, 2009, v. 16 n. 2, p. 104-112 How to Cite?
AbstractIt remains uncertain whether hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) and pregenomic RNA (pgRNA) can be detected in the serum or peripheral blood mononuclear cells (PBMC) of patients with chronic hepatitis B (CHB) infection. We examined HBV cccDNA and pgRNA in the serum and PBMC, and investigated the effect of lamivudine therapy on the viral loads in the PBMC of CHB patients. Paired serum and PBMC samples from 50 treatment-naïve CHB patients [25 hepatitis B e antigen (HBeAg) positive and 25 HBeAg negative] were quantified for total HBV DNA, cccDNA and pgRNA by real time polymerase chain reaction. HBV cccDNA and pgRNA were below the lower detection limit in all serum samples, and in 84% of PBMC. HBV DNA (r = 0.889, P < 0.001) and pgRNA (r = 0.696, P < 0.001) in PBMC correlated with the HBV DNA in serum. In the longitudinal study, 30 patients treated with lamivudine therapy for a median duration of 34 weeks (range 12-48 weeks) were examined. The median HBV DNA reduction in PBMC before and after treatment was 1.318 (range -0.471 to 3.846) log units, which was significantly lower than serum HBV DNA reduction [3.371 (range -0.883 to 9.454) log units, P < 0.05]. HBV cccDNA and pgRNA were undetectable in the serum of CHB patients. HBV viral loads in PBMC correlated with serum HBV DNA. Lamivudine therapy had less effect on the HBV viral loads in PBMC compared with the serum viral loads. © 2008 The Authors.
Persistent Identifierhttp://hdl.handle.net/10722/59348
ISSN
2023 Impact Factor: 2.5
2023 SCImago Journal Rankings: 1.078
ISI Accession Number ID
Funding AgencyGrant Number
National Basic Research Programme of China2007CB512800
RGC (HKU 7679/06M)
Cheng Si Yuan China
International Hepatitis Research Foundation
Funding Information:

This work was supported by the grants from the 973 National Basic Research Programme of China (2007CB512800), RGC (HKU 7679/06M) to Prof. George KK Lau and Cheng Si Yuan China - International Hepatitis Research Foundation.

References

 

DC FieldValueLanguage
dc.contributor.authorLu, Len_HK
dc.contributor.authorZhang, HYen_HK
dc.contributor.authorYueng, YHen_HK
dc.contributor.authorCheung, KFen_HK
dc.contributor.authorLuk, JMen_HK
dc.contributor.authorWang, FSen_HK
dc.contributor.authorLau, GKKen_HK
dc.date.accessioned2010-05-31T03:48:11Z-
dc.date.available2010-05-31T03:48:11Z-
dc.date.issued2009en_HK
dc.identifier.citationJournal Of Viral Hepatitis, 2009, v. 16 n. 2, p. 104-112en_HK
dc.identifier.issn1352-0504en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59348-
dc.description.abstractIt remains uncertain whether hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) and pregenomic RNA (pgRNA) can be detected in the serum or peripheral blood mononuclear cells (PBMC) of patients with chronic hepatitis B (CHB) infection. We examined HBV cccDNA and pgRNA in the serum and PBMC, and investigated the effect of lamivudine therapy on the viral loads in the PBMC of CHB patients. Paired serum and PBMC samples from 50 treatment-naïve CHB patients [25 hepatitis B e antigen (HBeAg) positive and 25 HBeAg negative] were quantified for total HBV DNA, cccDNA and pgRNA by real time polymerase chain reaction. HBV cccDNA and pgRNA were below the lower detection limit in all serum samples, and in 84% of PBMC. HBV DNA (r = 0.889, P < 0.001) and pgRNA (r = 0.696, P < 0.001) in PBMC correlated with the HBV DNA in serum. In the longitudinal study, 30 patients treated with lamivudine therapy for a median duration of 34 weeks (range 12-48 weeks) were examined. The median HBV DNA reduction in PBMC before and after treatment was 1.318 (range -0.471 to 3.846) log units, which was significantly lower than serum HBV DNA reduction [3.371 (range -0.883 to 9.454) log units, P < 0.05]. HBV cccDNA and pgRNA were undetectable in the serum of CHB patients. HBV viral loads in PBMC correlated with serum HBV DNA. Lamivudine therapy had less effect on the HBV viral loads in PBMC compared with the serum viral loads. © 2008 The Authors.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltden_HK
dc.relation.ispartofJournal of Viral Hepatitisen_HK
dc.rightsJournal of Viral Hepatitis. Copyright © Blackwell Publishing Ltd.en_HK
dc.subjectChronic hepatitis Ben_HK
dc.subjectHepatitis B virus DNAen_HK
dc.subjectPeripheral blood mononuclear cellsen_HK
dc.subjectPregenomic RNAen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshDNA, Viral - blooden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHepatitis B virus - isolation & purificationen_HK
dc.subject.meshHepatitis B, Chronic - drug therapy - virologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshLeukocytes, Mononuclear - chemistry - virologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPolymerase Chain Reaction - methodsen_HK
dc.subject.meshRNA, Viral - analysisen_HK
dc.subject.meshViral Loaden_HK
dc.subject.meshYoung Adulten_HK
dc.titleIntracellular levels of hepatitis B virus DNA and pregenomic RNA in peripheral blood mononuclear cells of chronically infected patientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1352-0504&volume=16&issue=2&spage=104&epage=112&date=2008&atitle=Intracellular+levels+of+hepatitis+B+virus+DNA+and+pregenomic+RNA+in+peripheral+blood+mononuclear+cells+of+chronically+infected+patientsen_HK
dc.identifier.emailLu, L: liweilu@hkucc.hku.hken_HK
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_HK
dc.identifier.authorityLu, L=rp00477en_HK
dc.identifier.authorityLuk, JM=rp00349en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1365-2893.2008.01054.xen_HK
dc.identifier.pmid19175882-
dc.identifier.scopuseid_2-s2.0-59149088774en_HK
dc.identifier.hkuros147157en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-59149088774&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume16en_HK
dc.identifier.issue2en_HK
dc.identifier.spage104en_HK
dc.identifier.epage112en_HK
dc.identifier.isiWOS:000262943400004-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLu, L=7403963552en_HK
dc.identifier.scopusauthoridZhang, HY=8965962000en_HK
dc.identifier.scopusauthoridYueng, YH=8965962100en_HK
dc.identifier.scopusauthoridCheung, KF=8763216400en_HK
dc.identifier.scopusauthoridLuk, JM=7006777791en_HK
dc.identifier.scopusauthoridWang, FS=7501310552en_HK
dc.identifier.scopusauthoridLau, GKK=7102301257en_HK
dc.identifier.citeulike4005461-
dc.identifier.issnl1352-0504-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats